Compare Cadila Healthcare with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ABBOTT INDIA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ABBOTT INDIA CADILA HEALTHCARE/
ABBOTT INDIA
 
P/E (TTM) x 28.2 46.7 60.4% View Chart
P/BV x 4.5 15.2 29.8% View Chart
Dividend Yield % 0.8 0.5 168.6%  

Financials

 CADILA HEALTHCARE   ABBOTT INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
ABBOTT INDIA
Mar-19
CADILA HEALTHCARE/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3528,834 4.0%   
Low Rs2075,458 3.8%   
Sales per share (Unadj.) Rs139.21,731.1 8.0%  
Earnings per share (Unadj.) Rs11.8211.9 5.6%  
Cash flow per share (Unadj.) Rs18.6219.9 8.4%  
Dividends per share (Unadj.) Rs3.5065.00 5.4%  
Dividend yield (eoy) %1.30.9 137.7%  
Book value per share (Unadj.) Rs101.4945.2 10.7%  
Shares outstanding (eoy) m1,023.7421.25 4,817.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.04.1 48.6%   
Avg P/E ratio x23.733.7 70.4%  
P/CF ratio (eoy) x15.032.5 46.3%  
Price / Book Value ratio x2.87.6 36.5%  
Dividend payout %29.830.7 97.0%   
Avg Mkt Cap Rs m286,033151,848 188.4%   
No. of employees `00013.43.5 384.6%   
Total wages/salary Rs m24,1454,356 554.3%   
Avg. sales/employee Rs Th10,632.710,555.5 100.7%   
Avg. wages/employee Rs Th1,801.21,249.9 144.1%   
Avg. net profit/employee Rs Th898.51,292.2 69.5%   
INCOME DATA
Net Sales Rs m142,53136,786 387.5%  
Other income Rs m1,1391,133 100.5%   
Total revenues Rs m143,67037,919 378.9%   
Gross profit Rs m24,1986,047 400.1%  
Depreciation Rs m6,965169 4,116.4%   
Interest Rs m3,41823 15,191.1%   
Profit before tax Rs m14,9546,989 214.0%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1982,485 128.7%   
Profit after tax Rs m12,0444,503 267.4%  
Gross profit margin %17.016.4 103.3%  
Effective tax rate %21.435.6 60.1%   
Net profit margin %8.512.2 69.0%  
BALANCE SHEET DATA
Current assets Rs m87,15427,610 315.7%   
Current liabilities Rs m82,6948,569 965.0%   
Net working cap to sales %3.151.8 6.0%  
Current ratio x1.13.2 32.7%  
Inventory Days Days7160 118.6%  
Debtors Days Days9427 342.4%  
Net fixed assets Rs m133,2361,057 12,606.4%   
Share capital Rs m1,024213 481.9%   
"Free" reserves Rs m102,73319,873 516.9%   
Net worth Rs m103,75720,086 516.6%   
Long term debt Rs m32,1460-   
Total assets Rs m236,86629,409 805.4%  
Interest coverage x5.4311.6 1.7%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.61.3 48.1%   
Return on assets %6.515.4 42.4%  
Return on equity %11.622.4 51.8%  
Return on capital %13.734.9 39.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,752369 14,297.5%   
Fx outflow Rs m14,5044,918 294.9%   
Net fx Rs m38,248-4,549 -840.7%   
CASH FLOW
From Operations Rs m25,0544,991 502.0%  
From Investments Rs m-10,123-2,570 393.9%  
From Financial Activity Rs m-10,942-1,428 766.2%  
Net Cashflow Rs m3,989993 401.6%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 7.9 105.1%  
FIIs % 5.9 0.1 5,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.1 64.3%  
Shareholders   44,069 18,270 241.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON   

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 22, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS